Angiotech receives favourable decision from the European Patent Office EPO
The EPO's Technical Board of Appeal rejected the attempt by Conor Medsystems Inc. and Sahajanand Medical Technologies Pvt. Ltd. to intervene and appeal an earlier decision by the Opposition Division of the European Patent Office, which upheld the Hunter patent. The decision found that these appeals were "inadmissible."
"We are pleased with the EPO's decision, and Angiotech views this outcome as yet another confirmation of the strength and validity of our patent portfolio," said Dr. William Hunter, President and CEO of Angiotech.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.